**why use combination immunotherapy?**

Combination immunotherapy can help the immune system attack cancer cells better than with one drug alone.

**Immunotherapy** includes antibodies, vaccines, viruses and other agents to make the immune system attack cancer cells.

**Combination Immunotherapy** is when more than one type of **checkpoint inhibitor** is combined to better block certain proteins.

**Immunotherapy** used for advanced RCC include interleukin-2 (IL-2), nivolumab, ipilimumab, pembrolizumab, avelumab.

**Examples include:** axitinib and avelumab, axitinib and pembrolizumab, bevacizumab and atezolizumab.

---

**risks and benefits**

While patients can benefit, there is a risk that healthy cells may be targeted. Autoimmune problems are usually manageable but, in rare cases, can be serious.

- Kidney cancer is among the **10 most common** cancers in the U.S.
- 90% of kidney cancers are **renal cell carcinoma (RCC).**
- 15% of patients using a combination immunotherapy to treat RCC **lived longer** than with one treatment.
- 9% of patients with advanced RCC were found to have **“no more signs of cancer”** after using combination immunotherapy in a clinical test.

---

**effective in treating kidney cancer**

- Kidney cancer is among the 10 most common cancers in the U.S.
- 90% of kidney cancers are renal cell carcinoma (RCC).
- 15% of patients using a combination immunotherapy to treat RCC lived longer than with one treatment.
- 9% of patients with advanced RCC were found to have “no more signs of cancer” after using combination immunotherapy in a clinical test.